Open innovation: A paradigm shift in pharma R&D?

Alexander Schuhmacher,Oliver Gassmann,Doria Bieniok,Markus Hinder,Dominik Hartl
DOI: https://doi.org/10.1016/j.drudis.2022.05.018
IF: 8.369
2022-06-02
Drug Discovery Today
Abstract:Open innovation (OI) holds promise to accelerate, diversify, and innovate research and development (R&D) in the pharmaceutical industry. It remains to be assessed in which way and to what extent OI is leveraged in practice by current pharmaceutical R&D organizations. Therefore, here we comprehensively analyzed 21 research-based pharmaceutical companies and benchmarked their implementation of OI. Our data showed that OI is an integral part of R&D of all assessed pharmaceutical companies; models...
pharmacology & pharmacy
What problem does this paper attempt to address?